The dysfunction in how Australia and New Zealand approach pharmaceutical reimbursement is not just procedural. It is rooted in how these systems think about themselves and the myths that sustain their authority. For years, debates over these programs have been channelled into technical terrain that the institution controls and comfortably defends. Institutions shield themselves through their own mythology, recasting policy choices as unquestionable truths. Real reform depends on challenging those myths and exposing the political decisions they conceal.
Process as power - how our institutions defend policy decisions by making them untouchable truths
October 30, 2025 Latest NewsBioPharmaComment 
		Latest Video
New Stories
- 
					
						The 'Dispatched' Week in Review Podcast - 31 OctoberOctober 31, 2025 - - Podcast
- 
					
						Aroa Biosurgery appoints Paul Shearer to Board as John Pinion retiresOctober 31, 2025 - - Australian Biotech
- 
					
						Immuron provides update on U.S. clinical trials for Travelan and IMM-529October 31, 2025 - - Australian Biotech
- 
					
						Firebrick Pharma launches new Nasodine Throat Spray for international marketsOctober 31, 2025 - - Australian Biotech
- 
					
						Amplia Therapeutics begins trading on U.S. OTCQB Venture MarketOctober 31, 2025 - - Australian Biotech
- 
					
						DHL Supply Chain opens New Zealand’s most advanced life sciences and healthcare logistics facilityOctober 31, 2025 - - Latest News
- 
					
						The continued 'false framing' aims to make us feel guilty for wanting more on healthOctober 31, 2025 - - Latest News
